Grifols S.A. (GRFS)
GRFS trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC filing XBRL, 20-F (ifrs-full:Revenue), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1438569/000110465926044901/0001104659-26-044901-index.htm. Net income: SEC 20-F (ifrs-full:ProfitLossAttributableToOwnersOfParent), fiscal year ended 2025-12-31. Converted from EUR at 0.9048 per USD (today's ECB or Federal Reserve reference rate).
Profile
| Field | Value |
|---|---|
| Ticker | GRFS on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | Spain |
| IPO year | Not reported by the screener |
| SEC CIK | 0001438569 |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $8.3B |
| Net income | $444.3M |
| Operating income | $1.4B |
| Net margin | 5.3% |
| Operating margin | 16.5% |
| Revenue growth | +4.3% |
| Cash | $911.8M |
| Total assets | $21.8B |
| P/E (computed) | 13.5× |
| P/S (computed) | 0.7× |
Reported in EUR; shown in US dollars.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 20-F 2026-04-17 |
| Cash and burn | 825.0M EUR cash; operating cash flow 261.8M EUR a quarter. | Report 2025-12-31 |
| Shares outstanding | No cover-page share count in XBRL | Cover page 2025-12-31 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Deloitte Auditores, S.L., Barcelona, Spain | PCAOB Form AP 2026-05-21 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Annual results
| Fiscal year | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| FY 2025 2025-12-31 | 7.5B EUR | 402.0M EUR | 1.0B EUR | 825.0M EUR | 160K EUR | 7.5B EUR | 20-F 2026-04-17 |
| FY 2024 2024-12-31 | 7.2B EUR | 156.9M EUR | 902.2M EUR | 979.8M EUR | 318.2M EUR | 7.2B EUR | 20-F 2025-04-11 |
| FY 2023 2023-12-31 | 6.6B EUR | 42.3M EUR | 218.7M EUR | 529.6M EUR | 674.3M EUR | 6.6B EUR | 20-F 2025-04-11 |
| FY 2022 2022-12-31 | 6.1B EUR | 185.0M EUR | -1.4M EUR | 549.2M EUR | 449.4M EUR | 6.1B EUR | 20-F 2025-04-11 |
| FY 2021 2021-12-31 | 4.9B EUR | 188.7M EUR | 597.0M EUR | 2.7B EUR | 330.0M EUR | 4.9B EUR | 20-F 2024-04-19 |
| FY 2020 2020-12-31 | 5.3B EUR | 618.5M EUR | 1.1B EUR | 579.6M EUR | 169.6M EUR | 5.3B EUR | 20-F 2023-04-18 |
| FY 2019 2019-12-31 | 5.1B EUR | 625.1M EUR | 568.9M EUR | 742.0M EUR | 186.0M EUR | 5.1B EUR | 20-F 2022-04-29 |
| FY 2018 2018-12-31 | 4.5B EUR | 596.6M EUR | 737.4M EUR | 1.0B EUR | 154.8M EUR | 4.5B EUR | 20-F 2021-04-09 |
From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months). Amounts in EUR.
Key SEC documents
The SEC filing list did not load in time for this page. It is on SEC EDGAR and in the full dossier.
Price moves
| Window | Return |
|---|---|
| 1 week | +3.1% |
| 1 month | +21.2% |
| 3 months | +9.6% |
| Year to date | -7.1% |
| 1 year | -0.1% |
| From 52-week high | -10.6% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| SUPN | Supernus Inc. | $28.83 | -2.99% | $6.0B |
| MIRM | Mirum Pharmaceuticals Inc. | $91.58 | -2.56% | $6.0B |
| LGND | Ligand Pharmaceuticals Incorporated | $301.71 | -2.29% | $6.0B |
| ARWR | Arrowhead Pharmaceuticals Inc. | $44.21 | -7.47% | $6.2B |
| BLTE | Belite Bio Inc | $162.56 | -1.09% | $6.5B |
| MANE | Veradermics Incorporated | $128.05 | -1.24% | $5.4B |
| ERAS | Erasca Inc. | $15.11 | -3.51% | $5.3B |
| PTCT | PTC Therapeutics Inc. | $60.97 | -3.97% | $5.1B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier